Ton Diepeveen Questions European Commission's Timing and Justification of Life Sciences Strategy

EU life sciences innovation is under the spotlight as Ton Diepeveen, a Member of the European Parliament from the PfE group, pushes the Commission to clarify the rationale behind launching a new strategy amid several ongoing initiatives. Diepeveen's inquiry is likely to stir interest among biotech firms, investors, public health authorities, and consumer advocates, all affected by potential shifts in regulatory and funding environments.

Diepeveen posed his questions in a formal written query, referencing the EU startup and scaleup strategy, the upcoming EU Biotech Act, and the medical countermeasures strategy. His questions scrutinize the Commission's decision to introduce an overarching Strategy for European Life Sciences (LSS) despite many of these individual efforts still being in developmental stages.

The Commission, represented by Ms. Zaharieva, responded that the LSS serves as a unifying framework announced in the Commission President’s 2024-2029 political guidelines. It seeks to coordinate and amplify existing and forthcoming initiatives without duplicating them. The response highlights that the strategy is built on comprehensive stakeholder consultations and studies like the Draghi report and evaluations of Horizon Europe. However, concrete measurable targets or new institutional structures were not detailed, rather the emphasis is on a coherent package of actions to enhance EU competitiveness in life sciences.

The policy leans towards increasing EU-level strategic coordination and regulatory adaptation to stimulate public and private investment in the sector. This implies a trade-off balancing innovation-friendly regulation with potential new oversight and investment mobilization demands.

The main stakeholders impacted include EU biotech companies (facing innovation-responsive regulation and investment opportunities), public and private investors (potentially unlocking new funding flows), EU public health bodies (benefitting from a framework aiming for rapid deployment of innovations), and consumers (whose access to advanced therapies might be accelerated but could face regulatory changes).

The Commission is expected to provide further elaboration and updates as the LSS-related initiatives unfold, marking important signals regarding the future direction of EU life sciences policy.